In this work, calcium oxalate (CaOx) precursors were stabilized by poly(acrylic acid) (PAA) as an additive under in vitro crystallization assays involving the formation of pre-nucleation clusters of CaOx via a non-classical crystallization (NCC) pathway. The in vitro crystallization of CaOx was carried out in the presence of 10, 50 and 100 mg/L PAA by using automatic calcium potentiometric titration experiments at a constant pH of 6.7 at 20 °C. The results confirmed the successful stabilization of amorphous calcium oxalate II and III (ACOII and ACO III) nanoparticles formed after PNC in the presence of PAA and suggest the participation and stabilization of polymer-induced liquid-precursor (PILP) in the presence of PAA. We demonstrated that PAA stabilizes CaOx precursors with size in the range of 20–400 nm. PAA additive plays a key role in the in vitro crystallization of CaOx stabilizing multi-ion complexes in the pre-nucleation stage, thereby delaying the nucleation of ACO nanoparticles. Indeed, PAA additive favors the formation of more hydrated and soluble phase of ACO nanoparticles that are bound by electrostatic interactions to carboxylic acid groups of PAA during the post-nucleation stage. These findings may help to a better understanding of the pathological mineralization resulting in urolithiasis in mammals.

Porcine circovirus type 2 (PCV2)-associated diseases are a major problem for the swine industry worldwide. In addition to improved management and husbandry practices, the availability of several anti-PCV2 vaccines provides an efficient immunological option for reducing the impact of these diseases. Most anti-PCV2 vaccines are marketed as injectable formulations. Although these are effective, there are problems associated with the use of injectable products, including laborious and time-consuming procedures, the induction of inflammatory responses at the injection site, and treatment-associated stress to the animals. Oral vaccines represent an improvement in antigen delivery technology; they overcome the problems associated with injection management and facilitate antigen boosting when an animals’ immunity falls outside the protective window. Chitosan microparticles were used as both a vehicle and mucosal adjuvant to deliver yeast-derived PCV2 virus-like particles (VLPs) in an attempt to develop an oral vaccine. The physical characteristics of the microparticles, including size, Zeta potential, and polydispersity, were examined along with the potential to induce PCV2-specific cellular immune responses in mice after oral delivery. Feeding mice with PCV2 VLP-loaded, positively-charged chitosan microparticles with an average size of 2.5 μm induced the proliferation of PCV2-specific splenic CD4+/CD8+ lymphocytes and the subsequent production of IFN-γ to levels comparable with those induced by an injectable commercial formulation. Chitosan microparticles appear to be a safe, simple system on which to base PCV2 oral vaccines. Oral chitosan-mediated antigen delivery is a novel strategy that efficiently induces anti-PCV2 cellular responses in a mouse model. Further studies in swine are warranted.

Electrically conducting elastomer composites based on natural rubber and reduced graphene oxide (rGO) is reported. These composites were prepared by a latex method and an easy washing process. The latex method consists of the mixing of an aqueous suspension of rGO, stabilized by sodium dodecyl sulfate and pre-vulcanized natural rubber, followed by solvent casting. The percolation threshold of composites was estimated at 1.54 wt.% of rGO. The washing process allowed elimination of the surfactant completely from nanocomposites. The absence of surfactant in nanocomposites was demonstrated by Raman spectroscopy and dynamo-mechanical analysis. The surfactant-free nanocomposites showed improved mechanical and electrical properties.